Dashboard
Manage Tickers

ARGXARGENX SE

Nasdaq argenx.com


$ 372.29 $ 4.20 (1.14 %)    

Friday, 26-Apr-2024 15:59:56 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 431.01 $ 6.55 (1.54 %)
DIA $ 382.27 $ 1.39 (0.36 %)
SPY $ 508.26 $ 4.77 (0.95 %)
TLT $ 88.26 $ 0.46 (0.52 %)
GLD $ 216.60 $ 0.70 (0.32 %)
$ 372.8
$ 370.30
$ 0.00 x 0
$ 0.00 x 0
$ 366.54 - $ 375.84
$ 327.73 - $ 550.76
281,322
na
22.07B
$ 0.82
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

the-analyst-verdict-argenx-in-the-eyes-of-12-experts
The Analyst Verdict: argenx In The Eyes Of...
04/18/2024 14:01:27

wedbush-reiterates-outperform-on-argenx-maintains-521-price-target
Wedbush Reiterates Outperform on argenx, M...
04/18/2024 13:21:52

Wedbush analyst David Nierengarten reiterates argenx (NASDAQ:ARGX) with a Outperform and maintains $521 price target.

hc-wainwright--co-reiterates-buy-on-argenx-maintains-451-price-target
HC Wainwright & Co. Reiterates Buy on arge...
04/18/2024 10:41:56

HC Wainwright & Co. analyst Douglas Tsao reiterates argenx (NASDAQ:ARGX) with a Buy and maintains $451 price target.

argenx-data-shows-evidence-that-vyvgart-and-vyvgart-hytrulo-deliver-transformative-results-for-patients-suffering-from-debilitating-autoimmune-diseases
argenx Data Shows Evidence That VYVGART An...
04/16/2024 07:18:27

ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years Real-world data demonstr...

cartesian-therapeutics-rare-disease-candidate-shows-long-lasting-benefit-over-argenxs-vyvgart-analyst-initiates-with-buy
Cartesian Therapeutics' Rare Disease Candi...
04/10/2024 18:34:58

Cartesian Therapeutics' autoimmune disease treatment with re-dosable mRNA CAR-Ts. Learn about Descartes-08, a promising ant...

hc-wainwright--co-maintains-buy-on-argenx-maintains-451-price-target
HC Wainwright & Co. Maintains Buy on argen...
03/27/2024 14:49:47

HC Wainwright & Co. analyst Douglas Tsao maintains argenx (NASDAQ:ARGX) with a Buy and maintains $451 price target.

argenx-announces-plan-to-continue-the-development-of-efgartigimod-primary-sjogrens-disease
argenx Announces Plan To Continue The Deve...
03/27/2024 07:06:00

RHO study supports proof-of-concept in primary Sjogren's disease Decision informed by favorable safety profile and consi...

key-takeaways-from-argenx-analyst-ratings
Key Takeaways From argenx Analyst Ratings
03/26/2024 19:01:17

tesla-to-120-here-are-10-top-analyst-forecasts-for-tuesday
Tesla To $120? Here Are 10 Top Analyst For...
03/26/2024 12:30:05

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

scotiabank-maintains-sector-perform-on-argenx-raises-price-target-to-408
Scotiabank Maintains Sector Perform on arg...
03/26/2024 11:24:44

Scotiabank analyst George Farmer maintains argenx (NASDAQ:ARGX) with a Sector Perform and raises the price target from $402 ...

argenx-receives-approval-of-vyvgart-in-japan-for-adults-with-primary-immune-thrombocytopenia
argenx Receives Approval Of VYVGART In Jap...
03/26/2024 07:15:42

VYVGART® now approved in Japan for both generalized myasthenia gravis and primary immune thrombocytopenia (ITP) Regulatory dec...

jmp-securities-reiterates-market-outperform-on-argenx-maintains-471-price-target
JMP Securities Reiterates Market Outperfor...
03/22/2024 17:08:55

JMP Securities analyst Jason Butler reiterates argenx (NASDAQ:ARGX) with a Market Outperform and maintains $471 price target.

why-factset-research-shares-are-trading-lower-by-around-5-here-are-other-stocks-moving-in-thursdays-mid-day-session
Why FactSet Research Shares Are Trading Lo...
03/21/2024 18:39:11

Shares of FactSet Research Systems Inc. (NYSE: FDS) fell sharply during Thursday’s session after the company reported worse-th...

guess-posts-upbeat-earnings-joins-lufax-nortech-systems-and-other-big-stocks-moving-higher-on-thursday
Guess? Posts Upbeat Earnings, Joins Lufax,...
03/21/2024 17:58:07

U.S. stocks were higher, with the Dow Jones index gaining around 250 points on Thursday.

why-is-european-pharma-giant-argenx-valued-at-over-20b-trading-higher-on-thursday
Why Is European Pharma Giant Argenx Valued...
03/21/2024 15:06:51

Argenx shares rise on Chugai's gMG trial disappointment. FDA-approved Vyvgart for anti-acetylcholine receptor antibody-posi...

12-health-care-stocks-moving-in-thursdays-pre-market-session
12 Health Care Stocks Moving In Thursday's...
03/21/2024 13:05:49

why-micron-therapies-shares-are-trading-higher-by-around-17-here-are-20-stocks-moving-premarket
Why Micron Therapies Shares Are Trading Hi...
03/21/2024 12:05:21

Shares of Micron Technology, Inc. (NASDAQ: MU) rose sharply in today’s pre-market trading as the company reported upbeat resul...

truist-securities-maintains-buy-on-argenx-raises-price-target-to-440
Truist Securities Maintains Buy on argenx,...
03/05/2024 12:40:19

Truist Securities analyst Joon Lee maintains argenx (NASDAQ:ARGX) with a Buy and raises the price target from $370 to $440.

scotiabank-maintains-sector-perform-on-argenx-raises-price-target-to-402
Scotiabank Maintains Sector Perform on arg...
03/01/2024 17:12:14

Scotiabank analyst George Farmer maintains argenx (NASDAQ:ARGX) with a Sector Perform and raises the price target from $346 ...

jmp-securities-maintains-market-outperform-on-argenx-raises-price-target-to-471
JMP Securities Maintains Market Outperform...
03/01/2024 16:34:59

JMP Securities analyst Jason Butler maintains argenx (NASDAQ:ARGX) with a Market Outperform and raises the price target from...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION